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Objectives. We investigated the relation between insulin and
coronary atherosclerosis and restenosis of the coronary arteries,
by performing elective percutaneous transluminal coronary an-
gioplasty (PTCA).
Background. Insulin is known to promote atherosclerosis of the
arteries and has been implicated in the development of restenosis
after PTCA.
Methods. Of 210 angina patients who underwent PTCA, newly
detected lesions in 35 consecutive nondiabetic subjects without
previous intervention on the same main coronary arteries were
analyzed after a 75-g oral glucose tolerance test (OGTT) and
follow-up coronary angiography. Atherosclerotic lesions were
evaluated by pattern, severity and extent. Restenosis was defined
as loss of gain, the percentage of loss of the initial gain in the
coronary diameter achieved by PTCA >250%.
Results. Patients with restenosis had a significantly higher
extent index (a marker of atherosclerosis), insulin area, ratio of
insulin area to glucose area, insulinogenic index and minimal
lumen diameter after PTCA than those without restenosis (p 5
0.001, 0.011, 0.002, 0.016 and 0.041, respectively). Simple regres-
sion analysis revealed that only the ratio of insulin area to glucose
area (a relative marker of enhanced insulin secretion) signifi-
cantly correlated with the extent index (p 5 0.035). Extent index,
insulin area, the ratio of insulin area to glucose area and
insulinogenic index significantly correlated with loss of gain (p 5
0.001, 0.010, 0.002 and 0.032, respectively). Stepwise multiple
regression analyses revealed that extent index and the ratio of
insulin area to glucose area significantly correlated with loss of
gain.
Conclusions. Enhanced secretion of insulin during the OGTT
might be useful as a predictor of coronary atherosclerosis and of
restenosis after elective PTCA in nondiabetic patients with effort
angina.
(J Am Coll Cardiol 1998;32:1624–9)
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Insulin is known to have a variety of in vivo actions, mainly in
the regulation of glucose metabolism in organs such as the
liver, and in muscle and adipose tissue mediated through
insulin receptors. Insulin has been reported to be involved in
the development of atherosclerosis, coronary heart disease, or
both through several mechanisms such as stimulation of cho-
lesterol synthesis, proliferation and migration of arterial
smooth muscle cells (1), increasing triglycerides and decreas-
ing high density lipoprotein (HDL) concentrations in plasma
(2) and binding of low density lipoprotein to both arterial
smooth muscle cells and monocyte macrophages (1). It has
also been reported that atherosclerosis was present at the site
of coronary vasospasm (3) and that hyperinsulinemia contrib-
utes to the pathogenesis of severe coronary vasospasm (4,5).
On the other hand, insulin has been reported to have
vasodilative effects mediated via an unidentified beta-
adrenergic mechanism (6), an inhibitory effect on norepineph-
rine and angiotensin-II–induced vasoconstriction (7) and anti-
thrombogenic actions through the augmentation of
prostacyclin synthesis (8). A definite outlook, however, of the
effect of insulin on the development of atherosclerosis and
restenosis after percutaneous transluminal coronary angio-
plasty (PTCA) is not clear to date. It is not only interesting but
also important to understand which is more important for the
development of atherosclerosis and restenosis, reduction of
insulin action or compensatory hyperinsulinemia. It has been
reported that enhanced sensitivity of the tissue to insulin by
thiazolidinedione reduces plasma levels of insulin, leading to a
favorable impact on several known cardiovascular risk factors
with non–insulin-dependent diabetes mellitus (9). This study
implicated the importance of restoration of the tissue sensitiv-
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ity to the actions of insulin; however, the question still remains
to be solved as to which is primarily important, higher concen-
tration of insulin per se or reduction of sensitivity to insulin, in
the development of atherosclerosis or restenosis, or both, after
PTCA.
On the basis of the information available today, it is very
important to investigate whether insulin really contributes to
the development of atherosclerosis, restenosis, or both, after
PTCA. We therefore designed this study to investigate the
effect of insulin on the development of coronary atherosclero-
sis and restenosis of the coronary arteries by performing
elective PTCA on nondiabetic, nonobese patients with effort
angina.
Methods
Study patients. From September 1993 through June 1997,
210 patients underwent elective PTCA for effort angina at
Kamo Hospital. The patients who underwent direct PTCA for
acute myocardial infarction or impending myocardial infarc-
tion or unstable angina were not included in this number. Of
the 210 patients, 35 consecutive nonobese, nondiabetic pa-
tients who had elective PTCA on 35 lesions in previously
nonintervened arteries were enrolled for the final analysis in
the present study. Exclusion criteria were 1) previous coronary
angioplasty at the same major artery (n 5 76), 2) history and
diagnosis of diabetes mellitus including the patients diagnosed
by the oral glucose tolerance test (OGTT) in this study after
the putative entry (n 5 68), 3) stent implantation or directional
coronary atherectomy (n 5 34), 4) failure of PTCA (n 5 14),
5) body mass index (BMI 5 body weight/height2) .28 kg/m2
(n 5 2), 6) complications of cardiogenic shock (n 5 1), 7)
patients without OGTT (n 5 22) and 8) patients without
follow-up coronary angiography because of transfer to other
institutions (n 5 11). According to these criteria, 175 patients
were excluded because they met more than one of these
criteria. All of the patients gave their informed consent to this
study.
Elective PTCA. Elective PTCA was performed within a few
days after the angiographic diagnosis of angina was made with
coronary arterial stenosis over 75% of reference diameter
(RD). Success of the PTCA was defined as a more than 20%
improvement in the percent diameter stenosis with less than
50% residual stenosis at the target lesion without a major
in-hospital complication within 1 month (death, Q-wave myo-
cardial infarction or need for bypass surgery or repeat angio-
plasty). Patients were treated with drugs such as nitrates,
calcium channel blockers, beta-blockers, angiotensin-
converting enzyme inhibitors and aspirin as standard medica-
tion for angina after PTCA.
Evaluation of atherosclerosis of coronary arteries by angio-
grams. Angiographic evaluations of the atherosclerosis of the
coronary arteries were performed by assessing three athero-
sclerotic indexes: pattern, severity and extent, essentially using
the criteria of Bogaty et al. (10), except for pattern, which was
classified as types A (minimally complex), B (moderately
complex) and C (severely complex) depending on the concen-
tricity, irregularity, angulation and tortuosity according to the
American College of Cardiology/American Heart Association
classification (11). Severity was evaluated by scoring as follows:
1) number of vessels diseased (.70% narrowing) of the 3
major coronary arteries (max 5 3), 2) total number of stenoses
($50% narrowing) in 15 segments of the arteries (max 5
15[max] 3 3[max] stenotic lesions in each segment 5 45) and
3) number of occlusions of the 3 major coronary arteries
(max 5 3). Extent, or the length of atherosclerotic injury, was
quantified by assigning a score of 0 (normal), 1 (abnormal: any
narrowing or irregularity or both #10% of the length), 2 (10 ,
abnormal #50%) or 3 (50% , abnormal) to each of the 15
segments of the arterial tree. Extent index was calculated by
dividing the extent score by the number of segments that could
be properly visualized by antegrade flow. Thus the extent index
could range from 0 (score of 0) to a maximum of 3 (score of 45
divided by 15 segments).
Measurement of cardiac angiogram. Follow-up coronary
angiography was performed about 31⁄2 months after PTCA.
Coronary arterial diameters were measured by quantitative
coronary arteriography with the use of a CAMAC-300
(GOODMAN Co., Nagoya, Japan) independently by two
cardiologists without any knowledge of the patient profiles,
and the mean value of the two measurements was used. The
percentage of the remaining stenosis in terms of the ratio of
the dilated arterial diameter to the corresponding RD (%
residual stenosis) was defined as (1-minimal lumen diameter
[MLD]/RD) 3 100, in which RD was determined by measuring
the lumen diameter proximal to the lesion. Loss of gain was
defined as a percentage of the loss of the initial gain in the
coronary diameter achieved by PTCA; therefore loss of gain 5
(1-MLD at follow-up coronary angiography/MLD after PTCA)
3 100. Restenosis was defined as loss of gain $50%.
Oral glucose tolerance test. A fasting blood sample from
each patient was obtained in the morning after overnight
fasting, and then a 75-g glucose solution was given orally.
Blood samples were obtained before (0) and 0.5, 1, 2 and 3 h
after the glucose load. Plasma levels of glucose were measured
by a glucose-dehydrogenase method with the use of a New
Glucorder analyzer (Analytical Instrument Co., Tokyo, Japan).
Plasma levels of insulin were measured by radioimmunoassay
with the use of an Insulin Riabead II (Dainabot Co., Tokyo,
Japan). Concentrations of glucose and insulin in plasma were
determined at all five time points, and the following indexes
were calculated: insulinogenic index (ratio of D plasma insulin
Abbreviations and Acronyms
BMI 5 body mass index
HDL 5 high density lipoprotein
MLD 5 minimal lumen diameter
OGTT 5 oral glucose tolerance test
PTCA 5 percutaneous transluminal coronary angioplasty
RD 5 reference diameter
1625JACC Vol. 32, No. 6 NISHIMOTO ET AL.
November 15, 1998:1624–9 INSULIN AND RESTENOSIS
to D plasma glucose, an index of insulin response to glucose
during the first 0.5 h of OGTT), insulin area (integration of
insulin concentrations over the 3-h period of OGTT), ratio of
insulin area to glucose area (insulin area divided by glucose
area; glucose area is the integration of glucose concentrations
over the 3-h period of OGTT). According to the recommen-
dation by the Japan Diabetes Society on the diagnosis of
diabetes mellitus, patients were diagnosed as having diabetes
mellitus when fasting plasma glucose was equal to or greater
than 140 mg/dL, plasma glucose 2 h after the load was equal to
or greater than 200 mg/dL, or both. When fasting plasma
glucose was less than 110 mg/dL, and glucose 1 and 2 h after
load was less than 160 mg/dL and less than 120 mg/dL,
respectively, the subjects were classified as normal. The pa-
tients having glucose levels other than described were diag-
nosed as having borderline diabetes mellitus. Factors of lipid
metabolism, total cholesterol, HDL cholesterol and triglycer-
ides, were analyzed in all subjects.
Statistical analysis. Results were expressed as mean 6 SD
in text, tables and figures. All of the statistical analyses were
performed using StatView Version 4.5 (Abacus Concepts, Inc.,
Berkeley, California). The unpaired t test was used for para-
metric data when normal distribution and equal dispersion
were recognized. Otherwise the Welch test or the Mann–
Whitney U test was used when appropriate. Differences in the
categorical data (gender, existence of borderline diabetes,
hypertension, etc.) between the two groups were analyzed by
the chi square test, and the Fisher exact test was used when
appropriate. Two-way repeated measures analyses of variance
followed by Scheffe’s multiple comparisons test were per-
formed for the evaluation of differences in the OGTT data
between the two groups or patients with and without resteno-
sis. Simple regression analyses were performed to analyze the
correlation between an index of atherosclerosis or extent index
and the patients’ basic characteristics (age, BMI, serum levels
of total cholesterol, HDL cholesterol, triglycerides) and OGTT
results. Also, simple regression analyses were performed to
investigate the correlation between an index of restenosis or
loss of gain and the basic characteristics, the atherosclerotic
indexes, OGTT results and PTCA data (RD, size of balloon, %
residual stenosis, MLD after PTCA, days to follow-up coro-
nary angiography). Stepwise multiple regression analyses were
performed to investigate the contributions of age, BMI, serum
levels of total cholesterol and triglycerides, fasting plasma
levels of glucose and insulin, the ratio of insulin area to glucose
area and insulinogenic index to extent index. Stepwise analyses
were also performed to investigate the contributions of age,
serum levels of total cholesterol, triglycerides, MLD after
PTCA, extent index, ratio of insulin area to glucose area and
days to follow-up coronary angiography to the loss of gain. p
Values ,0.05 were considered statistically significant.
Results
Patient characteristics. Table 1 shows clinical and PTCA
characteristics of patients with and without restenosis after
PTCA. The mean age of the 35 patients was 64.4 6 8.4 years
(mean 6 SD) and 28 patients (80%) were men. Twenty-two
patients (63%) were defined as having hypertension and 22
(63%) as being smokers. Mean BMI was 22.9 6 2.0 kg/m2.
Mean serum levels of total cholesterol, HDL cholesterol and
triglycerides were 202 6 38 mg/dL, 47.1 6 11 mg/dL and 131 6
85 mg/dL, respectively. Coronary angiography revealed that
newly developed responsible lesions for angina were in the left
anterior descending coronary artery in 17 (49%), in the right
coronary artery in 11 (31%) and in the left circumflex coronary
artery in 7 (20%). Before PTCA, mean MLD was 0.51 6
0.31 mm, mean RD was 2.8 6 0.6 mm and the size of balloon
used for PTCA was 2.7 6 0.5 mm. After PTCA, % residual
stenosis was 29.3 6 1.1% and mean MLD was 1.98 6 0.5 mm.
Restudy was performed 107 6 23 days (range: 70 to 161) after
PTCA.
Assessment for atherosclerotic indexes of coronary arteries.
To evaluate the association between the existence of coronary
atherosclerosis and the characteristics of these patients, simple
regression analyses were performed between extent index and
the clinical characteristics and OGTT results. Extent index was
significantly correlated only with the ratio of insulin area to
glucose area (R2 5 0.13, p 5 0.035). Stepwise multiple
regression analyses were performed to investigate an indepen-
dent contributor for the extent index among age, BMI, serum
levels of total cholesterol and triglycerides, fasting plasma
levels of glucose and insulin, the ratio of insulin area to glucose
area and insulinogenic index. These analyses demonstrated
that the ratio of insulin area to glucose area was the only
Table 1. Clinical and Percutaneous Transluminal Coronary Angioplasty
Characteristics in Patients With and Without Restenosis After
Percutaneous Transluminal Coronary Angioplasty
Characteristics
Restenosis (1)
(n 5 14)
Restenosis (2)
(n 5 21) p Value
Clinical
Borderline diabetes, n (%) 9 (64) 12 (57) NS
Age (yrs) 67.4 6 4.2 62.3 6 9.9 NS
Male, n (%) 12 (86) 16 (76) NS
Hypertension, n (%) 11 (79) 11 (52) NS
Smoker, n (%) 8 (57) 14 (67) NS
BMI (kg/m2) 23.4 6 1.9 22.6 6 2.1 NS
Total cholesterol (mg/dL) 201 6 36 203 6 40 NS
HDL cholesterol (mg/dL) 48.1 6 13.8 46.5 6 9.8 NS
Triglycerides (mg/dL) 144 6 113 122 6 67 NS
PTCA
Size of balloon (mm) 2.61 6 0.49 2.68 6 0.48 NS
RD (mm) 2.57 6 0.54 2.93 6 0.60 NS
% residual stenosis 31.8 6 6.5 27.6 6 11.8 NS
MLD after PTCA (mm) 1.75 6 0.39 2.13 6 0.58 0.041
Lesion, n (LAD/LCX/RCA) 7/2/5 10/5/6 NS
Days to restudy 109 6 24 107 6 23 NS
Data are presented as mean 6 SD. BMI 5 body mass index; HDL 5 high
density lipoprotein; LAD 5 left anterior descending coronary artery; LCX 5 left
circumflex coronary artery; MLD 5 minimal lumen diameter; NS 5 not
significant; PTCA 5 percutaneous transluminal coronary angioplasty; RCA 5
right coronary artery; RD 5 reference diameter.
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parameter that correlated with the extent index or the exis-
tence of coronary atherosclerosis (R2 5 0.13, p 5 0.035).
Evaluation of the patients with and without restenosis.
Restenosis was observed in 14 of 35 patients (40%). Neither
clinical nor PTCA (Table 1) characteristics of these patients,
except for MLD after PTCA, showed significant correlation
with the development of restenosis. The MLD after PTCA was
significantly (p , 0.05) smaller in patients with restenosis than
in those without restenosis. Scorings of atherosclerotic indexes
and results of the OGTT in patients with and without resten-
osis are shown in Tables 2 and 3, respectively. Among the
atherosclerotic indexes, extent index, or the length of the
atherosclerotic lesion, was the only variable which was shown
to be significantly associated with restenosis (p 5 0.001).
Among the OGTT results, insulin area, the ratio of insulin area
to glucose area and the insulinogenic index were shown to be
significantly associated with restenosis (p 5 0.011, 0.002 and
0.016, respectively). No other variables were significantly asso-
ciated with restenosis. Changes in plasma levels of glucose and
insulin during the 3 h of OGTT in these patients are depicted
in Figure 1. Although the plasma levels of glucose did not differ
significantly between patients with and without restenosis, the
plasma levels of insulin were significantly higher (p 5 0.007) in
patients with restenosis during the early phase of the OGTT or
at 30 min (p 5 0.005) and 1 h (p 5 0.037) after the glucose
load.
Assessment for restenosis after PTCA. To study associa-
tions between the development of restenosis or loss of gain and
the patients’ characteristics, the atherosclerotic indexes,
OGTT results and PTCA variables, simple regression analyses
were performed between loss of gain and these variables. Loss
of gain was significantly correlated with extent index (R2 5
0.31, p 5 0.001), insulin area (R2 5 0.19, p 5 0.009), the ratio
of insulin area to glucose area (R2 5 0.25, p 5 0.002) and
insulinogenic index (R2 5 0.13, p 5 0.032). Other variables did
not significantly correlate to loss of gain. Stepwise multiple
regression analyses were also performed to determine whether
clinical results, PTCA characteristics, the atherosclerotic in-
dexes and OGTT results were to be independent contributors
of loss of gain. These analyses revealed that extent index and
the ratio of insulin area to glucose area were the only two
independent variables that significantly correlated with loss
Table 2. Atherosclerotic Indexes in Patients With and Without
Restenosis After Percutaneous Transluminal Coronary Angioplasty
Restenosis (1)
(n 5 14)
Restenosis (2)
(n 5 21) p Value
Pattern, n(typeA/B/C) 0/14/0 4/16/1 NS
Severity
Vessels diseased 1.43 6 0.65 1.14 6 0.36 NS
Stenoses 2.93 6 1.90 2.24 6 1.41 NS
Occlusions 0.50 6 0.65 0.19 6 0.40 NS
Extent index 1.34 6 0.15 0.93 6 0.38 0.001
Data are presented as mean 6 SD. NS 5 not significant; PTCA 5
percutaneous transluminal coronary angioplasty; pattern 5 classification of the
changes in the pattern of atherosclerotic lesion according to American College of
Cardiology/American Heart Association standards (ref. 11); severity 5 athero-
sclerotic severity of the lesion scored by vessels diseased (.70% narrowing) and
the total number of stenoses ($50% narrowing) in 15 segments (15 3 [0–3] 5
0–45), and occlusions of the three major coronary arteries (0–3); extent index is
calculated by dividing extent score 0 (normal), 1 (abnormal: any narrowing or
irregularity #10% of the length, or both), 2 (10 , abnormal #50%), 3 (50% ,
abnormal) to each of the 15 segments of the arterial tree ([0–3] 3 15 5 0–45)
by the number of segments properly visualized by antegrade flow (0–15),
accordingly ranging from 0 to 3. Extent score was not calculated when antegrade
flow was not detected at the particular segment.
Table 3. Oral Glucose Tolerance Test Results in Patients With and Without Restenosis After
Percutaneous Transluminal Coronary Angioplasty
Restenosis (1)
n 5 14
Restenosis (2)
n 5 21
p
Value
Fasting plasma glucose (mg/dL) 88.5 6 8.4 93.3 6 9.1 NS
Glucose area (mg/dL 3 h) 376 6 65 395 6 100 NS
Fasting plasma insulin (mU/mL) 6.14 6 2.98 5.52 6 4.24 NS
Insulin area (mU/mL 3 h) 214 6 112 130 6 73 0.011
Insulin area/glucose area 0.56 6 0.24 0.33 6 0.17 0.002
Insulinogenic index 1.21 6 0.65 0.60 6 0.72 0.016
Data are presented as mean 6 SD. NS 5 not significant.
Figure 1. The results of the OGTT in patients with (solid circles) and
without (open circles) restenosis. The x axis shows time after glucose
load (h). Data are presented as mean (circles) 6 SD (bars). *p , 0.05;
**p , 0.01.
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of gain or the development of restenosis after PTCA (R2 5
0.41, p , 0.001).
Discussion
Patient characteristics. In this study we excluded the pa-
tients who had a history of previous PTCA on the same major
coronary artery in which the responsible lesion for effort
angina was newly diagnosed. This exclusion criterion was
applied to eliminate the influences of factors of the injury
induced by previous PTCA and of the healing process that may
cause complex and diverse effects on the development of
atherosclerosis or restenosis or both. We also excluded the
patients with diabetes mellitus because their metabolic re-
sponses to glucose load, including the release of insulin and the
uptake of glucose, are considered to be abnormal, thus affect-
ing the results of the OGTT. To elucidate a specific mechanism
or a predictor of restenosis after PTCA, patients who had
undergone directional atherectomy (n 5 4) were excluded in
this study because directional atherectomy is considered to
cause more profound injuries to coronary vasculature than
balloon angioplasty. These exclusion criteria were applied to
make the interpretation of the OGTT results as straightfor-
ward as possible with regard to the effect of insulin on
atherosclerosis or restenosis after PTCA. These two exclusion
criteria substantially decreased the number of patients for final
analysis; however, these exclusion criteria were critically im-
portant for the analyses and interpretation of our results to
avoid presumably huge and strong effects of the preceding
injury on coronary arteries by PTCA and of diabetes mellitus
on the metabolism of coronary vasculature.
Coronary atherosclerosis. It has been known that diabetes
mellitus is a risk factor of coronary atherosclerosis (12,13). In
more recent studies it has been shown that elevated fasting
insulin (14,15), or postload insulin (1,14,16), is associated with
coronary artery disease. In the present study, we found that the
extent index, an index of the degree of coronary atherosclero-
sis, significantly and positively correlated with the ratio of
insulin area to glucose area. This result may indicate that the
ratio of insulin area to glucose area, reflecting the enhanced
secretion of insulin relative to plasma glucose level, can serve
as a predictor or an indicator of the existence of coronary
atherosclerosis, if checked when patients develop effort angina.
Several mechanisms by which insulin is involved in the devel-
opment of coronary atherosclerosis have been reported:
through stimulating arterial smooth muscle cell proliferation
(1), aggravating dyslipidemia (16,17), modulating metabolisms
of several bioactive substances such as procoagulant or anti-
coagulant factors and several growth factors (15). It is note-
worthy here that insulin area did not, but the ratio of insulin
area to glucose area did, significantly correlate with the extent
index in our population of nondiabetic patients with angina.
This result suggests that not insulin per se, but the ratio of
insulin to glucose or a relative surplus of insulin is a very
important factor in the development of coronary atheroscle-
rosis. This result may also suggest that the effect of insulin on
vessel walls is attenuated, or that a condition like “insulin
resistance,” as in the organs and tissues of hyperinsulinemic
patients (18), is developed in the coronary arteries of these
patients. In other words, attenuated responses of coronary
arteries to the enhanced secretion of insulin in these patients
would account for the failure of the insulin area but the success
of the ratio of insulin area to glucose area as a significant
predictor of the existence of atherosclerosis.
Restenosis after PTCA. Diabetes mellitus (19), length of
stenotic lesions (20), residual percent diameter (20) and MLD
after PTCA (21) have been reported as risk factors of resten-
osis after PTCA. The present study is the first to report that
enhanced secretion of insulin observed until 1 h after the
glucose load is an independent predictor of restenosis after
elective PTCA in nondiabetic, nonobese patients with effort
angina. Mechanisms underlying the development of restenosis
after PTCA are currently considered to be derived from elastic
recoil (22), thrombus formation (23–25), proliferation and
migration of smooth muscle cells (26) or mixtures of secondary
effects, such as the secretion of stimulatory factors for smooth
muscle cell proliferation (27). Insulin is considered at least in
part to be directly or indirectly involved in all of these
mechanisms of restenosis. Insulin is known to potentiate
proliferation and migration of smooth muscle cells directly, or
indirectly through the secretion of stimulatory factors for the
proliferation (1,28,29). Long-term recoil of the overstretched
arteries by PTCA is proposed to be derived from the replace-
ment of the injured medial smooth muscle cells by the prolif-
erated cells (22). This replacement process will be theoretically
stimulated by the action of insulin. Insulin has also been
reported to be involved in thrombus formation through atten-
uating endogenous fibrinolytic activities by modulating the
plasminogen activator and inhibitor systems (30). In more
recent studies of restenosis, exaggerated intimal hyperplasia
has been observed in restenotic lesions of the arteries after
various types of coronary intervention (31), and smooth muscle
cell proliferation has been implicated to the increased rate of
restenosis through the action of insulin (19). Because insulin
has a wide variety of actions with regard to the development of
atherosclerosis or of coronary restenosis or both, it is difficult
to pinpoint the definitive mechanism as to how the enhanced
secretion of insulin after glucose load leads to the development
of restenosis after PTCA in patients with effort angina.
Restenosis after PTCA and coronary atherosclerosis. This
study confirmed a strong correlation between the extent of
preceding coronary atherosclerosis or extent index and the
development of restenosis or loss of gain in our study patients.
Although possibly different mechanisms are functioning be-
tween the progression of coronary atherosclerosis and the
development of restenosis after PTCA, arterial endothelial
injury as the first step of atherosclerosis (32) is inevitable in the
coronary arteries on which PTCA was performed. Proliferation
of coronary arterial smooth muscle cells lying just beneath the
endothelial cells damaged by PTCA will be stimulated repeat-
edly by the enhanced insulin secretion following the ingestion
of foods or glucose load, resulting in the acceleration of
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restenosis. Enhanced secretion of insulin after glucose load
significantly correlated with both extent index and loss of gain,
but the correlation coefficients were larger with the marker of
restenosis (loss of gain) than that of atherosclerosis (extent
index). This result may suggest that the enhanced insulin
secretion exerts more rapid and profound effects on prolifer-
ation of smooth muscle cells in the coronary arteries mechan-
ically damaged by PTCA than in those chronically damaged by
atherosclerosis.
Study limitations. Our study group was small because of
the strict inclusion criteria adopted for final analysis of the
patients. We evaluated the development of restenosis by
relatively early restudies at an angiographic follow-up of 107 6
23 days after PTCA. The present study would therefore have
been underpowered to detect the difference in specific vari-
ables, to include all of the restenosis for the analysis and to
exclude possible artifacts from the analysis.
Conclusions. In this study we found that nondiabetic pa-
tients with effort angina who showed enhanced secretion of
insulin during the OGTT have a high risk not only for coronary
atherosclerosis but also for restenosis after elective PTCA.
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